Elizabeth k. Hale
Larisa J Geskin, MD, FAAD
Associate Professor of Dermatology in Medicine

Columbia University Medical Center
New York, USA
Phone:  212-305-5550
E-mail: ljg2145@cumc.columbia.edu




University of Pittsburgh School of Medicine



Albert Einstein College of Medicine, Bronx, New York


Dr. Larisa Geskin is an Associate Professor of Dermatology in Medicine at Columbia University Medical Center and Director of the Comprehensive Skin Cancer Center (CSCC) at the Department of Dermatology.

Dr. Geskin is a world renowned specialist in the diagnosis and management of cutaneous lymphomas. Her other areas of expertise include non-melanoma skin cancers and melanoma screening, prevention, medical and surgical therapy, and management of high risk populations. Dr. Geskin is leading a multidisciplinary team to provide care to cutaneous lymphoma patients and to conduct cutting edge clinical and translational research. She is also involved in training of the medical students, residents and fellows in the area of cutaneous oncology. Dr. Geskin completed her residency in Dermatology at University of Pittsburgh Medical Center (UPMC), and, a two-year fellowship in cutaneous oncology at University of Pittsburgh Cancer Institute (UPCI) with John Kirkwood, MD, Professor and Vice Chairman for Clinical Research, Director of the Melanoma Center at the UPCI. She is a diplomat of the American Academy of Dermatology, member of the Society for Investigative Dermatology, the International Society for Cutaneous Lymphomas, US Cutaneous Lymphomas Consortium, and New York Academy of Sciences. She authored over 60 peer-reviewed articles in the field of cutaneous oncology. Her research interest focuses on Cutaneous T-cell lymphoma (CTCL) and biomarkers discovery, genetic profiling and regulation, development of immunotherapy for melanoma and lymphoma.


Research Interest

  • Biomarkers discovery in CTCL
  • Genetic profiling and regulation in CTCL
  • Development of Immunotherapy for melanoma and Cutaneous T-cell lymphoma (CTCL)
  • Evaluation of immune suppression in CTCL and role of immunotherapies in its improvement
  • Discovery of etiology of CTCL, including evaluation for novel viruses
  • Evaluation of the role of environmental hazards in etiology of CTCL
  • Assessment of efficacy of the novel therapeutic agents for therapy of CTCL in clinical trials
  • Use of novel high throughput technologies for CTCL and melanoma research
  • Age-related immunological changes in patients with CTCL


Professional Activities:

Teaching Activities:


Associate Professor of Dermatology, Columbia University Medical Center


Associate Professor of Dermatology, University of Pittsburgh School of Medicine


Director of Dermatology Residency Program, University of Pittsburgh Medical Center


Assistant Professor of Dermatology, University of Pittsburgh School of Medicine


Director, Cutaneous Oncology Center, University of Pittsburgh Medical Center


Associate Director Dermatological Branch, UPCI Melanoma Center


Visiting Instructor, University of Pittsburgh School of Medicine 

Professional Activities:


New York Consortium for Cutaneous Lymphomas


Association of Professors in Dermatology


United States Cutaneous Lymphoma Society


Leaders Society, Dermatology Foundation


New York Academy of Sciences


International Society for Cutaneous Lymphomas


Dermatology Foundation


American Academy of Dermatology
Society for Investigative Dermatology

Honors & Awards:


Teacher of the Year Award Columbia Residency Dermatology Program


The Leading Physicians of the World (International Association of Dermatologists)


Sheldon Adler Award for Innovation in Medica Education (UPSoM Committee)


Best Doctors in Pennsylvania


Physician Scientist Career Development Award (Dermatology Foundation)


Young Investigator’s Award (Cutaneous Lymphoma Foundation)


A Dermatologist Investigator Research Fellowship Award (Dermatology Foundation)
ACES – UPMC Award for Commitment and Excellence in Service


GCRC Clinical Research Feasibility Funds (CReFF) Program Award



  1. Child F, Ortiz-Romero PL, Alvarez R, Bagot M, Stadler R, Weichenthal M, Alves R, Quaglino P, Beylot-Barry M, Cowan R, Geskin LJ, Pérez-Ferriols A, Hellemans P, Elsayed Y, Phelps C, Forslund A, Kamida M, Zinzani PL. Phase II Multicenter Trial of Oral Quisinostat, a Histone Deacetylase Inhibitor, in Patients with Previously Treated Stage IB-IVA Mycosis Fungoides/Sézary Syndrome. Br J Dermatol. 2016 Feb 2. doi: 10.1111/bjd.14427.
  2. Dulmage BO, Akilov O, Vu JR, Falo LD, Geskin LJ. Dysregulation of the TOX-RUNX3 pathway in cutaneous T-cell lymphoma. Oncotarget. 2015 Nov. doi: 10.18632/oncotarget.5742.
  3. Geskin LJ. Monoclonal Antibodies. Dermatol Clin. 2015 Oct;33(4):777-86. doi: 10.1016/j.det.2015.05.015
  4. M Cheng, W Johnson, L Geskin, J Ho, L Grandinetti. Simultaneous diagnosis of cutaneous T-cell lymphoma, chronic lymphocytic leukemia, and acute myelogenous leukemia: Treatment and management challenges. Journal of the American Academy of Dermatology 72 (5), AB163-AB163.
  5. S Shaigany, NA Weitz, S Husain, L Geskin, ME Grossman. A case of lymphomatoid granulomatosis presenting with cutaneous lesions. JAAD Case Reports 1 (4), 234-237. 2015
  6. R Tang, L Geskin, ME Grossman. Pyoderma gangrenosum in a patient with cutaneous T-cell lymphoma. JAAD Case Reports 1 (2), 93-95. 2015
  7. Dulmage BO, Villaseñor-Park J, Ho J, Geskin LJ, Grandinetti LM. Tumor Stage Mycosis Fungoides in a Child. Pediatr Dermatol. 2015 Apr 17. doi: 10.1111/pde.12570
  8. Bates SE, Eisch R, Ling A, Rosing D, Turner M, Pittaluga S, Prince HM, Kirschbaum MH, Allen SL, Zain J, Geskin LJ, Joske D, Popplewell L, Cowen EW, Jaffe ES, Nichols J, Kennedy S, Steinberg SM, Liewehr DJ, Showe LC, Steakley C, Wright J, Fojo T, Litman T, Piekarz RL. Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data. Br J Haematol. 2015 Apr 19. doi: 10.1111/bjh.13400
  9. Geskin LJ, Viragova S, Stolz DB, Fuschiotti P. Interleukin-13 is over-expressed in cutaneous T-cell lymphoma cells and regulates their proliferation. Blood. 2015 Jan 27. pii
  10. Dulmage BO, Story SK, Falo LD Jr, Geskin LJ. Novel therapeutic combination demonstrates more than additive effects in cutaneous T-cell lymphoma. Leuk Lymphoma. 2015 Jan 21:1-3.
  11. Dulmage BO, Feng H, Mirvish E, Geskin L.  Black cat in a dark room: the absence of a directly oncogenic virus does not eliminate the role of an infectious agent in cutaneous T-cell lymphoma pathogenesis. Br J Dermatol. 2014 Nov 10.
  12. Moreau JF, Buchanich JM, Geskin JZ, Akilov OE, Geskin LJ. Non-random geographic distribution of patients with cutaneous T-cell lymphoma in the Greater Pittsburgh Area. Dermatol Online J. 2014 Jul 15;20(7).
  13. Dummer R, Duvic M, Scarisbrick J, Olsen EA, Rozati S, Eggmann N, Goldinger SM, Hutchinson K, Geskin L, Illidge TM, Giuliano E, Elder J, Kim YH. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome). Ann Oncol. 2014 Sep;25(9):1807-12
  14. Story SK, Petrov AA, Geskin LJ. Successful desensitization to brentuximab vedotin after hypersensitivity reaction. J Drugs Dermatol. 2014 Jun;13(6):749-51
  15. Geskin LJ, Akilov OE, Lin Y, Lokshin AE. Distinct age-matched serum biomarker profiles in patients with cutaneous T-cell lymphoma. Exp Dermatol. 2014 Aug;23(8):598-600
  16. Schowalter MK, Dulmage BO, Ho J, Vu JR, Falo LD Jr, Geskin LJ. Comparative proteomic analysis reveals unique tumor protein composition among the melanoma subtypes pure desmoplastic and superficial spreading. Melanoma Res. 2014 Aug;24(4):397-400.
  17. Dulmage BO, Geskin LJ. Lessons learned from gene expression profiling of cutaneous T-cell lymphoma. Br J Dermatol. 2013 Dec;169(6):1188-97
  18. Mirvish JJ, Pomerantz RG, Falo LD, Geskin LJ. Role of infectious agents in cutaneous T-cell lymphoma: Facts and controversies. Clinics in Dermatology. 2013 Jul-Aug; 31(4):423-31
  19. Duvik M, Geskin LJ, Prince HM. Duration of Response in Cutaneous T-cell Lymphoma patients treated with Denileukin Diftitol: Results from 3 Phase III Studies. Clin Lymphoma Myeloma Leuk. 2013 Aug 13(4):377-84.
  20. Koch E, Story SK, Geskin LJ. Preemptive Leucovorin Administration Minimizes Pralatrexate Toxicity without Sacrificing Efficacy. Leuk Lymphoma. 2013 Feb. (Ahead of print)
  21. Story SK, Schowalter MK,  Geskin LJ. Breast Implant-Associated ALCL: A unique entity in the Spectrum of CD30+ Lymphoproliferative Disorders. The Oncologist. 2013;18(3):301-7. Epub 2013 Feb 21.
  22. McCann S, Akilov OE, Geskin LJ. Adverse effects of Denileukin Diftitox and their management in patients with cutaneous T-cell lymphoma. Clinical Journal of Oncology Nursing. 2012 Oct.; 16(5): 495
  23. Knobler R, Duvic M, Querfeld C, Straus D, Horwitz S, Zain J, Kuzel T, Duvic M, Parenti D, Geskin LJ. Long-term follow-up and survival of cutaneous T-cell lymphoma (CTCL) patients treated with extracorporeal photopheresis (ECP). Photodermatol Photoimmunol Photomed. 2012 Oct;(28)5:250-257
  24. Schowalter MK, Akilov OE, Story S, Geskin LJ. Cutaneous manifestations of PTCL-u may be indicative of the disease activity and predict response to therapy. JCO 2012 Oct 1;30(28):e283-5. PMID: 22869871
  25. Akilov OE, Wu MX, Ustyugova IV, Falo LD Jr, Geskin LJ. Resistance of Sezary cells to TNF-α-induced apoptosis is mediated in part by a loss of TNFR1 and a high level of the IER3 expression. Exp Dermatol. 2012 Apr; 21(4):287-92. PMID: 22417305
  26. Akilov OE, Grant C, Frye R, Bates S, Piekarz R, Geskin LJ. Low-Dose Electron Beam Radiation and Romidepsin Therapy for Symptomatic Cutaneous T-cell Lymphoma Lesions. Br J Dermatol, 2012 Feb. 28.doi: 10.1111/j.1365-2133.2012.10905.x. PMID:22372971
  27. Olsen E, Whittaker S, Kim Y, Duvic M, Prince HM, Lessin S, Wood G, Willemze R, Demierre M, Pimpinelli N, Bernengo M, Ortiz-Romero P, Bagot M, Estrach T, Guitart J, Knobler R, Sanches J, Iwatsuki K, Sugaya M, Dummer R, Pittelkow M, Hoppe R, Parker S, Geskin LJ, Pinter-Brown L, Girardi M, Burg G, Ranki A, Vermeer M, Horwitz S, Heald P, Rosen S, Cerroni L, Dreno B, Vonderheid EC.  Clinical endpoints and response criteria in Mycosis Fungoides and Sezary Syndrome: a consensus statement of the International Society for Cutaneous Lymphomas (ISCL), the United States Cutaneous Lymphoma Consortium (USCLC) and the Cutaneous Lymphoma Task Force of the European Organization for Research and Treatment of Cancer (EORTC).  Journal of Clinical Oncology.  29(18)2598-2607; 2011 Jun 20
  28. Akilov OE, Pillai R, Grandinetti L, Kant J, Geskin LJ. Clonal T-Cell Receptor γ-Chain Gene Rearrangements in Differential Diagnostics of Lymphomatoid Papulosis from Skin Metastasis of Nodal Anaplastic Large Cell Lymphoma. Arch of Dermatology, 147 (8):943-947, 2011 Aug
  29. Talpur R, Demierre MF, Geskin L, Baron E, Pugliese S, Eubank K, Zic JA, Miller DR, Tharp M, Bohjanen K, Duvic M. Multicenter photopheresis intervention trial in early-stage mycosis fungoides. Clin Lymphoma Myeloma Leuk. 2011 Apr;11(2):219-27. Epub 2011 Apr 8.
  30. Akilov OE, Wu MX, Jin Y, Zhou Z, Geskin LJ, Falo LD, Hasan T. Vaccination with photodynamic therapy-treated macrophages induces highly suppressive T-regulatory cells. Photodermatol Photoimmunol Photomed. 2011 Apr;27(2):97-107.




Autoimmune Journal Flyer